Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1-CAR T Therapy in Relapsed/Refractory CS1+ Multiple Myeloma
NCT03710421Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Apr 2019
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCARTCS1 in multiple myeloma (MM), sponsored by City of Hope. Primary endpoints: Incidence of dose-limiting toxicity at 12 months, Incidence of all other toxicities at 15 years and 2 more. Started Apr 2019; status: suspended.
02
Drugs
UCARTCS1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03710421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710421.